And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
After Merck’s success with a P2X3 inhibitor hopes were high for Bellus’s similar compound. They are now dashed.